Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The continuously evolving phenotype of succinic semialdehyde dehydrogenase deficiency

  • Julia-Palacios, Natalia Alexandra|||0000-0002-2560-3970
  • Kuseyri Hübschmann, Oya|||0000-0001-6576-6566
  • Olivella, Mireia|||0000-0002-6035-3399
  • Pons, Roser|||0000-0001-6749-1906
  • Horvath, Gabriella|||0000-0003-2573-2489
  • Lücke, Thomas
  • Fung, Cheuk-Wing|||0000-0002-0105-1673
  • Wong, Suet-Na
  • Cortès-Saladelafont, Elisenda|||0000-0002-8604-2230
  • Rovira-Remisa, M Mar
  • Yıldız, Yilmaz
  • Mercimek-Andrews, Saadet
  • Assmann, Birgit|||0000-0003-0458-953X
  • Stevanović, Galina
  • Manti, Filippo|||0000-0002-2012-8410
  • Brennenstuhl, Heiko
  • Jung-Klawitter, Sabine|||0000-0001-8851-672X
  • Jeltsch, Kathrin
  • Sivri, H Serap|||0000-0001-8260-9984
  • Garbade, Sven F.|||0000-0002-7420-4757
  • García-Cazorla, Àngels
  • Opladen, Thomas|||0000-0003-4349-7662
The objective of the study is to evaluate the evolving phenotype and genetic spectrum of patients with succinic semialdehyde dehydrogenase deficiency (SSADHD) in long-term follow-up. Longitudinal clinical and biochemical data of 22 pediatric and 9 adult individuals with SSADHD from the patient registry of the International Working Group on Neurotransmitter related Disorders (iNTD) were studied with in silico analyses, pathogenicity scores and molecular modeling of ALDH5A1 variants. Leading initial symptoms, with onset in infancy, were developmental delay and hypotonia. Year of birth and specific initial symptoms influenced the diagnostic delay. Clinical phenotype of 26 individuals (median 12 years, range 1.8-33.4 years) showed a diversifying course in follow-up: 77% behavioral problems, 76% coordination problems, 73% speech disorders, 58% epileptic seizures and 40% movement disorders. After ataxia, dystonia (19%), chorea (11%) and hypokinesia (15%) were the most frequent movement disorders. Involvement of the dentate nucleus in brain imaging was observed together with movement disorders or coordination problems. Short attention span (78.6%) and distractibility (71.4%) were the most frequently behavior traits mentioned by parents while impulsiveness, problems communicating wishes or needs and compulsive behavior were addressed as strongly interfering with family life. Treatment was mainly aimed to control epileptic seizures and psychiatric symptoms. Four new pathogenic variants were identified. In silico scoring system, protein activity and pathogenicity score revealed a high correlation. A genotype/phenotype correlation was not observed, even in siblings. This study presents the diversifying characteristics of disease phenotype during the disease course, highlighting movement disorders, widens the knowledge on the genotypic spectrum of SSADHD and emphasizes a reliable application of in silico approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis

  • Villacieros-Álvarez, Javier
  • Espejo, Carmen|||0000-0001-9949-5901
  • Arrambide, Georgina|||0000-0002-2657-5510
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Carbonell-Mirabent, Pere|||0000-0003-1349-9261
  • Rodriguez, Marta
  • Bollo, Luca|||0000-0002-3673-2030
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Galan, Ingrid|||0000-0001-5774-4260
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Mongay-Ochoa, Neus|||0000-0002-0338-4797
  • Nos, Carlos|||0000-0002-3830-4910
  • Río, Jordi|||0000-0003-4546-7627
  • Rodríguez Acevedo, Breogán|||0000-0002-0314-753X
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Tur, Carmen|||0000-0003-1849-3184
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Vilaseca, Andreu|||0000-0001-8147-8505
  • Zabalza, Ana|||0000-0003-3860-5251
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
Objective: Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) distinguish multiple sclerosis (MS) from MOG-associated disease in most cases. However, studies analyzing MOG-Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG-Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG-Ab+) and seronegative (MOG-Ab-) patients. Methods: Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG-Ab were analyzed using a live cell-based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. Results: MOG-Ab were positive in 17 of 630 (2.7%). Fourteen out of 17 (82.4%) MOG-Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37.0%) MOG-Ab- patients (p = 0.009). Cerebrospinal fluid-restricted oligoclonal bands (CSF-OBs) were found in 2 of 16 (12.5%) MOG-Ab+ versus 371 of 601 (61.7%) MOG-Ab- subjects (p < 0.001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52.9%) MOG-Ab+ versus 153 of 585 (26.2%) MOG-Ab- patients (p = 0.029). Absence of CSF-OBs and ON at onset were independently associated with MOG-Ab positivity (odds ratio [OR] = 9.03, 95% confidence interval [CI] = 2.04-53.6, p = 0.009; and OR = 4.17, 95% CI = 1.15-19.8, p = 0.042, respectively). Of MOG-Ab+ patients, 22.9% (95% CI = 0.0-42.7) compared to 67.6% (95% CI = 63.3-71.3) of MOG-Ab- patients fulfilled McDonald 2017 criteria at 5 years (log-rank p = 0.003). Interpretation: MOG-Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF-OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2024;95:116-128.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of endoplasmic reticulum stress-associated lncRNAs influencing inflammation and VSMC function in abdominal aortic aneurysm

  • Almendra-Pegueros, Rafael|||0000-0002-4411-4515
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Cáncer, Susana
  • Pérez-Marlasca, Elvira|||0000-0001-9815-198X
  • Medina-Gómez, Gema|||0000-0001-8169-681X
  • Martínez-González, José|||0000-0002-3894-7166
  • Garcia Redondo, Ana B.|||0000-0002-5815-3320
  • Galán, María|||0000-0002-4758-8388
Endoplasmic reticulum (ER) stress plays a critical role in the abdominal aortic aneurysm (AAA), a life-threatening disease characterized by inflammation, destructive remodeling, and vascular smooth muscle cells (VSMCs) dysfunction. The current therapy relies on surgical repair, but no effective pharmacological strategies are available to limit aneurysm progression. Long non-coding RNAs (lncRNAs) are essential factors in health and disease; however, their specific contribution to AAA development and its relationship with ER stress remain unexplored. Here, we have performed a whole-genome transcriptomic analysis characterizing the expression profile of lncRNAs in AAA. RNA sequencing was carried out in abdominal aorta from patients with AAA and healthy donors. We identified 6576 differentially expressed (DE)-mRNAs and 1283 DE-lncRNAs. Interestingly, bioinformatic analysis revealed a set of 368 DE-lncRNAs related to ER stress. The differential expression of the most induced lncRNAs (IL-21-AS1, ITPKB-IT, PCED1B-AS1, TCL-6, LINC00494, LINC00582, LINC00626, LINC00861, and LINC00892) was validated in a large cohort of patients with AAA. The ability of these selected lncRNAs to discriminate patients with AAA from healthy subjects was established by receiveroperating characteristic curves and logistic regression analysis. In human aortic VSMC and Jurkat T-cells, tunicamycin-induced ER stress triggered the expression of IL21-AS1, LINC00626, LINC00494, LINC00892, PCED1B-AS1, ITPKB-IT, and TCL-6, while tauroursodeoxycholic acid counteracted these effects. Finally, an integrated analysis of mRNA-lncRNA co-expression revealed the correlation between the selected lncRNAs and the DE-mRNAs involved in immune response and muscle contraction. Therefore, these DE-lncRNAs potentially implicated in the ER stress response, a pathological process in AAA, could be considered as potential therapeutic target to handle AAA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Neurocognitive Impairment in Inherited Metabolic Disorders due to Intoxication and Energy Defects, A Systematic Review

  • Gil-González, Marta
  • Arias, Carolina
  • Saudubray, Jean-Marie
  • Colomé-Roura, Roser
  • García-Cazorla, Ángeles
Inherited metabolic disorders (IMD) can disrupt brain development and functioning, leading to cognitive and behavioral abnormalities. This systematic review aims to provide a comprehensive synthesis of the evidence regarding neurocognitive impairments in intoxication IMD due to the accumulation of small molecule disorders and energy-related IMD. A search was conducted in the PubMed database until August 2024, using the term "cognition" and up to 421 energy-related IMD and 196 intoxication IMD. Reviews, animal models, studies with non-standardized measures, and studies that focused on complex molecule disorders, small molecule deficiencies, and phenylketonuria were excluded. In total, 163 studies were included in the final analysis. The cognitive domains assessed were executive functions, attention, processing speed, language, speech, visual performance, fine motor dexterity, memory, behavioral and emotional regulation, and social cognition. Most available evidence focused on intoxication IMD (83%), which exhibited better global cognitive functioning than energy defects. The cognitive domains most frequently reported as impaired were fine motor dexterity (80.9%), behavioral and emotional regulation (80%), executive functions (73.3%), attention (72.4%), and social cognition (65.6%). After applying the chi-square test with a 95% confidence level, no statistically significant differences were found between intoxication and energy-related IMD. However, language impairments were slightly more pronounced in intoxication disorders, while visuospatial deficits were more common in energy disorders. Individuals with IMD are at a higher risk of neurodevelopmental disorders, which can persist despite early detection and treatment. Although the number of cognitive studies has increased in recent years, further research with standardized measures is necessary to understand the underlying pathophysiology of neurocognitive impairments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

  • Rueda, Ariana|||0000-0001-7588-9279
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Aviñó, Ana|||0000-0003-3047-738X
  • Fabrega, Carme|||0000-0003-3816-7634
  • Eritja, Ramon|||0000-0001-5383-9334
  • Paez, David|||0000-0002-5596-6588
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an alternative, we previously developed a multivalent protein nanocarrier (T22-GFP-H6) displaying the CXCR4-targeting peptide T22, which offers super-selective tumor accumulation driven by CXCR4 overexpression. This innovative nanovehicle showed favorable biodistribution for targeted delivery of antitumor drugs, including monomethyl auristatin E (MMAE), in a first-generation stochastic nanoconjugate format. However, unlike ADCs, where conjugation strategy is known to influence pharmacokinetics and efficacy, these parameters remain largely unexplored in non-antibody multivalent nanocarriers. Here, we evaluated the impact of precise payload accommodation using two site-specific strategies that attach a single MMAE molecule at distinct structural sites, and we compared them with first-generation nanoconjugates. The conjugation strategy substantially affected the biodistribution and antitumor efficacy, with a solvent-exposed cysteine-conjugation distal to the targeting ligand proving most effective. At equimolar nanocarrier dosing, this construct achieved tumor control similar to the stochastic conjugate in a disseminated hematologic malignancy despite an approximately 4-fold lower MMAE load (drug-to-protein ratio, DPR = 1 vs DPR ≈ 4). Moreover, at equimolar MMAE dosing, it clearly outperformed both the stochastic conjugate and the alternative site-directed design. These findings align with trends in advanced ADCs and provide practical design rules for rational, site-specific conjugation in next-generation protein-based nanomedicines aimed at enabling dose-sparing in oncology.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation

  • Delgado-Arija, Marta
  • Genovés, Patricia
  • Pérez-Carrillo, Lorena
  • González-Torrent, Irene
  • Giménez-Escamilla, Isaac
  • Martínez-Dolz, Luis
  • Portolés, Manuel
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
[EN] Background Cardiac fibroblast activation protein (FAP) has an emerging role in heart failure (HF). A paradoxical reduction in its levels in pathological conditions associated with acute processes has been observed. We aimed to identify FAP cardiac tissue expression and its relationship with the main cardiac fibrosis-related signaling pathways, and to compare plasma FAP levels in acute and chronic HF patients. Methods Transcriptomic changes were assessed via mRNA/ncRNA-seq in left ventricle tissue from HF patients (n¿=¿57) and controls (n¿=¿10). Western blotting and immunohistochemistry were used to explore FAP protein levels and localization in cardiac tissue. ELISA was performed to examine plasma FAP levels in acute HF (n¿=¿48), chronic HF (n¿=¿15) and control samples (n¿=¿7). Results FAP overexpression in cardiac tissue is related to the expression of molecules directly involved in cardiac fibrosis, such as POSTN, THBS4, MFAP5, COL1A2 and COL3A1 (P¿<¿0.001), and is directly and inversely related to pro- and antifibrotic microRNAs, respectively. The observed FAP overexpression is not reflected in plasma. Circulating FAP levels were lower in acute HF patients than in controls (P¿<¿0.05), while chronic HF patients did not show significant changes. The clinical variables analyzed, such as functional class or etiology, do not affect plasma FAP concentrations. Conclusions We determined that in HF cardiac tissue, FAP is related to the main cardiac fibrosis signaling pathways as well as to pro- and antifibrotic microRNAs. Additionally, an acute phase of HF decreases plasma FAP levels despite the upregulation observed in cardiac tissue and regardless of other clinical conditions., This work was supported by the National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III [Projects: PI20/01469 and PI20/00071 co-funded by European Union; Miguel Servet contracts: CP18/00145 co-funded by European Union, European Social Fund (ESF) The ESF invests in your future and CP21/00041 co-funded by European Union; contract FI21/00186 and FI21/00034]; Consorcio Centro de Investi&#8209; gación Biomédica en Red [CIBERCV, under Grant CB16/11/00261]; Ministry of Universities and the European Recovery, Transformation and Resilience Plan (PRTR, Next Generation EU) [ Ayuda Margarita Salas para la formación de jóvenes doctores : contract: MS21-162]; Ministry of Science and Innovation (MCIN, 10.13039/501100011033) and State Investigation Agency (AEI) [Project CNS2022-135769] co-funded by European Union Next Generation EU and PRTR; Conselleria de educación, universidades y empleo [Project CIA&#8209; ICO/2022/246, contract CIACIF/2022/429].
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro

  • Herranz, Raquel
  • Oto, Julia
  • Hueso, Marta
  • Plana, Emma
  • Cana, Fernando
  • Castaño, Maria
  • Cordon, Lourdes
  • Ramos-Soler, David
  • Bonanad, Santiago
  • Vera-Donoso, César D.
  • Martínez-Sarmiento, Manuel
  • Medina, Pilar
[EN] Background: Neutrophils, key players of the immune system, also promote tumor development through the formation of neutrophil extracellular traps (NETs) in a process called NETosis. NETs are extracellular networks of DNA, histones and cytoplasmic and granular proteins (calprotectin, myeloperoxidase, elastase, etc.) released by neutrophils upon activation. NETs regulate tumor growth while promoting angiogenesis and invasiveness, and tumor cells also stimulate NETosis. Although NETosis seems to be increased in cancer patients, an increase of NETs in plasma may also be mediated by an impaired degradation by plasma DNaseI, as evidenced in several immunological disorders like lupus nephritis. However, this has never been evidenced in bladder cancer (BC) patients. Herein, we aimed to evaluate the occurrence of increased NETosis in plasma and tumor tissue of BC patients, to ascertain whether it is mediated by a reduced DNaseI activity and degradation, and to in vitro explore novel therapeutic interventions. Methods: We recruited 71 BC patients from whom we obtained a plasma sample before surgery and a formalin-fixed paraffin embedded tumor tissue sample, and 64 age- and sex-matched healthy controls from whom we obtained a plasma sample. We measured NETs markers (cell-free fDNA, calprotectin, nucleosomes and neutrophil elastase) and the DNaseI activity in plasma with specific assays. We also measured NETs markers in BC tissue by immunofluorescence. Finally, we evaluated the ability of BC and control plasma to degrade in vitro-generated NETs, and evaluated the performance of the approved recombinant human DNaseI (rhDNaseI, Dornase alfa, Pulmozyme (R), Roche) to restore the NET-degradation ability of plasma. In vitro experiments were performed in triplicate. Statistical analysis was conducted with Graphpad (v.8.0.1). Results: NETosis occurs in BC tissue, more profusely in the muscle-invasive subtype (P<0.01), that with the worst prognosis. Compared to controls, BC patients had increased NETosis and a reduced DNaseI activity in plasma (P<0.0001), which leads to an impairment to degrade NETs (P<0.0001). Remarkably, this can be therapeutically restored with rhDNaseI to the level of healthy controls. Conclusion: To the best of our knowledge, this is the first report demonstrating that BC patients have an increased NETosis systemically and in the tumor microenvironment, in part caused by an impaired DNaseI-mediated NET degradation. Remarkably, this defect can be therapeutically restored in vitro with the approved Dornase alfa, thus Pulmozyme (R) could become a potential therapeutic tool to locally reduce BC progression., This research was supported by research grants from Instituto de Salud Carlos III (PI17/00495, PI20/00075, PI20/01171, FI21/00171), Sociedad Espanola de Trombosis y Hemostasia (SETH) and co-financed by the European Union through the Operational Programme European Regional Development Fund (FEDER) of the Valencian Community 2014-2020. All these are non-profit organizations, and therefore are not involved in the design of the study, experimental/clinical work, data analyses or interpretation, and preparation of the manuscript.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Tesis doctoral (DoctoralThesis)

Study of PD-1/LAG-3 signaling in T cells and development of therapeutic strategies to counteract PD-1/LAG-3 mediated resistance to cancer immunotherapy, Estudio de la señalización de PD-1/LAG-3 en los linfocitos T, y desarrollo de estrategias terapéuticas para contrarrestar la resistencia a la inmunoterapia del cáncer mediada por PD-1/LAG-3

  • Chocarro de Erauso, Luisa
El tutor de la tesis es Ignacio José Encío Martínez, A significant number of cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells. However, how LAG-3 mechanistically triggers its downstream inhibitory signalling remains largely unknown. Likewise, how LAG-3 cooperates with PD-1 to stablish a highly dysfunctional state in T cells in cancer is also unknown. A better understanding of LAG-3 and PD-1/LAG-3 signaling will uncover the reasons behind intrinsic resistance to PD-1 blockade, develop novel treatments and improve current therapies. This PhD thesis comprises the study of PD-1/LAG-3 signaling in T-cells and the development of therapeutic strategies to counteract PD-1/LAG-3-mediated resistance to cancer immunotherapy. The results of this thesis have been organized into three chapters. In chapter 1, PD-1/LAG-3 molecular co-signaling mechanisms were identified in T-cells, uncovering CBLB ubiquitin ligases as potential targets. The combination of CBL-B inhibitors with anti-PD- 1/anti-LAG-3 immunotherapies overcame PD-1/LAG-3-mediated resistance in models of lung cancer refractory to immunotherapies. In chapter 2, the consequences of PD-1/LAG-3 cosignaling over the proteome and phosphoproteome associated to the TCR signalosome were characterized. MYC was identified as an inhibited upstream regulator of PD-1/LAG-3 proteomes and phosphoproteomes in T-cells. In chapter 3, T-cell lines expressing LAG-3 mutants in its signaling domains were engineered and analyzed by quantitative highthroughput differential proteomics and phosphoproteomics. The pathways and molecules regulated by each of LAG-3 domains and their effect on the TCR signalosome both in terms of protein expression and phosphorylation activity were characterized. These results highlighted the critical role of KIEELE and EP domains to endow LAG-3 with inhibitory functions. Overall, the results will help to identify the mechanisms of intrinsic resistance to PD-1 blockade mediated by LAG-3 co-signaling, and uncover novel therapeutic targets to counteract PD- 1/LAG-3-mediated resistance., Financiada por el Instituto de Salud Carlos III (ISCIII), co-financiada por el Fondo Europeo de Desarrollo Regional (fondos FEDER) y el Fondo Social Europeo 'Contratos PFIS: Contratos Predoctorales de Formación en Investigación en Salud' (FI21/00080) para el desarrollo de esta tesis doctoral; y por el Instituto de Salud Carlos III (ISCIII), co-financiada por El Fondo Europeo de Desarrollo Regional (fondos FEDER) y el Fondo Social Europeo 'Ayudas para la movilidad del personal investigador (Modalidad M-AES)' (MV22/00123) para realizar una estancia doctoral internacional de seis meses en University College London (UCL), optando así a la mención de Doctor Internacional., Programa de Doctorado en Ciencias de la Salud (RD 99/2011), Osasun Zientzietako Doktoretza Programa (ED 99/2011)
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

  • de Gonzalo Calvo, David
  • Molinero, Marta
  • Benítez, Iván D.
  • Perez Pons, Manel
  • García Mateo, Nadia
  • Ortega, Alicia
  • Postigo, Tamara
  • García Hidalgo, María C.
  • Belmonte, Thalía
  • Rodríguez Muñoz, Carlos
  • González, Jessica
  • Torres, Gerard
  • Gort Paniello, Clara
  • Moncusí Moix, Anna
  • Estella García, Ángel
  • Tamayo Lomas, Luis
  • Martínez de la Gándara, Amalia
  • Socias, Lorenzo
  • Peñasco, Yhivian
  • de la Torre, María del Carmen
  • Bustamante Munguira, Elena
  • Gallego Curto, Elena
  • Martínez Varela, Ignacio
  • Martín Delgado, María Cruz
  • Vidal Cortés, Pablo
  • López Messa, Juan
  • Pérez García, Felipe
  • Caballero, Jesús
  • Añón, José Manuel
  • Loza Vázquez, Ana
  • Carbonell, Nieves
  • Marin Corral, Judith
  • Jorge García, Ruth Noemí
  • Barberà, Carmen
  • Ceccato, Adrián
  • Fernández Barat, Laia
  • Ferrer, Ricard
  • García Gasulla, Dario
  • Lorente Balanza, Jose Ángel
  • Menéndez, Rosario
  • Motos, Ana
  • Peñuelas, Oscar
  • Riera, Jordi
  • Bermejo Martin, Jesús F.
  • Torres, Antoni
  • Barbé, Ferrán
Background: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. Methods: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. Results: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways. Conclusions: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients., 11 páginas
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

El poder del comedor escolar como herramienta de salud: sinergias entre la política pública y el programa E-DUCASS, The impact of the school lunchroom as a health tool: Synergies between public policy and the E-DUCASS program

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease

  • Núñez-Sánchez, María Ángeles
  • Martínez-Sánchez, María Antonia
  • Sierra-Cruz, Marta
  • Lambertos, Ana
  • Rico-Chazarra, Sara
  • Oliva-Bolarín, Alba
  • Balaguer-Román, Andrés
  • Yuste, Jose E.
  • Martínez, Carlos Manuel
  • Mika, Adriana
  • Frutos, María Dolores
  • Llamoza-Torres, Camilo J.
  • Córdoba-Chacón, José
  • Ramos-Molina, Bruno
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver condition that often progresses to more advanced stages, such as metabolic dysfunction-associated steatohepatitis (MASH). MASH is characterized by inflammation and hepatocellular ballooning, in addition to hepatic steatosis. Despite the relatively high incidence of MASH in the population and its potential detrimental effects on human health, this liver disease is still not fully understood from a pathophysiological perspective. Deregulation of polyamine levels has been detected in various pathological conditions, including neurodegenerative diseases, inflammation, and cancer. However, the role of the polyamine pathway in chronic liver disorders such as MASLD has not been explored. In this study, we measured the expression of liver ornithine decarboxylase (ODC1), the rate-limiting enzyme responsible for the production of putrescine, and the hepatic levels of putrescine, in a preclinical model of MASH as well as in liver biopsies of patients with obesity undergoing bariatric surgery. Our findings reveal that expression of ODC1 and the levels of putrescine, but not spermidine nor spermine, are elevated in hepatic tissue of both diet-induced MASH mice and patients with biopsy-proven MASH compared with control mice and patients without MASH, respectively. Furthermore, we found that the levels of putrescine were positively associated with higher aspartate aminotransferase concentrations in serum and an increased SAF score (steatosis, activity, fibrosis). Additionally, in in vitro assays using human HepG2 cells, we demonstrate that elevated levels of putrescine exacerbate the cellular response to palmitic acid, leading to decreased cell viability and increased release of CK-18. Our results support an association between the expression of ODC1 and the progression of MASLD, which could have translational relevance in understanding the onset of this disease. © 2024 The Pathological Society of Great Britain and Ireland, We are particularly grateful for the generous contribution of the patients and the collaboration of Biobank Network of the Region of Murcia, BIOBANC-MUR, registered on ‘Registro Nacional de Biobancos’ with registration number B.0000859. BIOBANC-MUR was supported by the ‘Instituto de Salud Carlos III (proyecto PT20/00109)’, by ‘Instituto Murciano de Investigación Biosanitaria, IMIB’ and ‘Consejería de Salud de la Comunidad Autónoma de la Región de Murcia’. Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) (awards numbers R01DK131038, R03DK129419) and by the Institute of Health Carlos III (ISCIII) (award numbers PI20/00505 and PI23/00171). MÁNS is supported by the ‘Miguel Servet’ program (CP23/00051, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER); MAMS is supported by a PFIS predoctoral fellowship from the ISCIII (FI21/00003, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER); and BRM is supported by the ‘Miguel Servet’ program (CP19/00098, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER), Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma

  • Parejo-Alonso, Beatriz
  • Royo-García, Alba
  • Espiau-Romera, Pilar
  • Courtois, Sarah
  • Curiel-García, Álvaro
  • Zagorac, Sladjana
  • Villaoslada, Isabel
  • Olive, Kenneth P.
  • Heeschen, Christopher
  • Sancho, Patricia
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease characterized by its metastatic potential and chemoresistance. These traits are partially attributable to the highly tumorigenic pancreatic cancer stem cells (PaCSCs). Interestingly, these cells show unique features in order to sustain their identity and functionality, some of them amenable for therapeutic intervention. Screening of phospho-receptor tyrosine kinases revealed that PaCSCs harbored increased activation of anaplastic lymphoma kinase (ALK). We subsequently demonstrated that oncogenic ALK signaling contributes to tumorigenicity in PDAC patient-derived xenografts (PDXs) by promoting stemness through ligand-dependent activation. Indeed, the ALK ligands midkine (MDK) or pleiotrophin (PTN) increased self-renewal, clonogenicity and CSC frequency in several in vitro local and metastatic PDX models. Conversely, treatment with the clinically-approved ALK inhibitors Crizotinib and Ensartinib decreased PaCSC content and functionality in vitro and in vivo, by inducing cell death. Strikingly, ALK inhibitors sensitized chemoresistant PaCSCs to Gemcitabine, as the most used chemotherapeutic agent for PDAC treatment. Consequently, ALK inhibition delayed tumor relapse after chemotherapy in vivo by effectively decreasing the content of PaCSCs. In summary, our results demonstrate that targeting the MDK/PTN-ALK axis with clinically-approved inhibitors impairs in vivo tumorigenicity and chemoresistance in PDAC suggesting a new treatment approach to improve the long-term survival of PDAC patients.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A contributory citizen science project reveals the impact of dietary keys to microbiome health in Spain

  • Pons Tarín, Marc
  • Cognard, Chloe
  • Noguera Segura, Arnau
  • Roca-Bosch, Melina
  • Soler, Zaida
  • Serrano Gómez, Gerard
  • Vega Abellaneda, Sara
  • xie, zixuan
  • Manjon, Isaac
  • Varela Castro, Encarna
  • Yañez, Francisca
  • Chaysavanh, Manichanh
Contributory citizen science; Dietary keys; Microbiome, Ciencia ciudadana contributiva; Claves dietéticas; Microbioma, Ciència ciutadana contributiva; Claus dietètiques; Microbioma, Low consumption of whole grains, fruits, and vegetables has been identified as dietary risks for non-communicable diseases such as inflammatory bowel diseases (IBDs). We explore how individual and lifestyle factors influence these risks by shaping gut microbiome composition. 1001 healthy participants from all Spanish regions provided personal and dietary data at baseline, six, and twelve months, yielding 2475 responses. Gut microbiome data were analyzed for 500 healthy participants and 321 IBD patients. Our findings reveal that adherence to national dietary guidelines—characterized by diets rich in nuts, seeds, fruits, and vegetables—was associated with greater microbial diversity and reduced IBD-related dysbiosis. Finally, we observed variations in dietary patterns and microbiome diversity and composition across age groups, genders, regions, seasons, and transit time. This study is among the first to uncover dietary intake associated with IBD-related dysbiosis and to propose an interactive website for participants (https://manichanh.vhir.org/POP/en)., This work was financially supported by the Instituto de Salud Carlos III and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future” (PI20/00130; FI21/00262) and by the AGAUR (2021 SGR 00459). Francisca Yáñez was supported by a fellowship from ANID, BECAS Chile, No. 72190278. None of the funders were private companies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

  • Lunemann, Jan
  • Valls Carbó, Adrián
  • Fernández, Victoria
  • Villacieros-Álvarez, Javier
  • Sepulveda, Maria
  • Dinoto, Alessandro
  • Vilaseca Jolonch, Andreu
  • Castillo Juárez, Mireia
  • Espejo, Carmen
  • Cobo-Calvo, Alvaro
  • Tintore, Mar
  • Comabella Lopez, Manuel
  • Arrambide, Georgina
  • Montalban, Xavier
  • Bollo, Luca
Complement activation; Clinical outcomes; Myelin oligodendrocyte glycoprotein, Perfiles de activación; Resultados clínicos; Glucoproteína de oligodendrocito de mielina, Activació del complement; Resultats clínics; Glicoproteïna d'oligodendròcits de mielina, Background and Objectives The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD. Methods Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples. A panel of CFs were measured by multiplex ELISA, and the levels were compared between the 3 conditions. Univariable and multivariable analyses were performed to evaluate the association between levels of CFs and relapse and disability outcomes in MOGAD patients. Results Ninety-four patients (MOGAD, n = 60; MS, n = 18; AQP4-NMOSD, n = 16) were included. Mean (SD) age at sampling was 39.4 (16.7), 40.7 (7.0), and 43.3 (21.0), respectively. Female were predominant, especially in AQP4-NMOSD (88%). Combination of the serum levels of C3a, C4a, and C3a/C3 ratio showed excellent potential to discriminate MOGAD from patients with MS (area under the curve [AUC] [95% CI] 0.95 [0.90–0.99]) and from AQP4-NMOSD (AUC 0.88 [0.76–1.00]). In patients with MOGAD, CSF levels of CFs of the classical/lectin pathway influenced relapse-related outcomes, and lower C4 levels were associated with higher number of relapses during follow-up (incidence rate ratio [95% CI] 0.88 [0.78–0.99]; p = 0.04 in multivariable analysis), and a high C4a/C4 ratio was associated with increased risk of second relapse during the first year (hazard ratio [95% CI] 3.68 [1.26–10.78]; p = 0.02 in multivariable analysis). Time to second relapse was shorter in patients with MOGAD with a high CSF C4a/C4 ratio (log-rank p = 0.01). CSF levels of the membrane attack complex SC5b9 influenced disability-related outcomes, and baseline CSF SC5b9 levels were higher in patients who reached the final Expanded Disability Status Scale (EDSS) ≥ 3.0 (p = 0.002), and elevated SC5b9 levels were associated with increased risk of reaching EDSS ≥ 3.0 (odds ratio [95% CI] 1.79 [1.16–3.67]; p = 0.04 in multivariable analyses). Discussion Our results suggest that serum and CSF levels of CFs have diagnostic and prognostic value respectively in patients with MOGAD. These findings support the use of complement inhibitors as a therapeutic approach in these patients., The study was funded thanks to a legacy from Mrs. Adela Arbó. J.V.-A. received grant from Instituto de Salud Carlos III, Spain; FI21/00282.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease

  • Mulero, Patricia
  • Rubio-Flores, Laura
  • Villacieros-Álvarez, Javier
  • Espejo, Carmen
  • Dinoto, Alessandro
  • Rovira, Alex
  • Auger, Cristina
  • Tintore, Mar
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
  • Montalban, Xavier
Serum Cytokines; Prognosis; Myelin oligodendrocyte glycoprotein, Citocinas séricas; Pronóstico; Glicoproteína de oligodendrocitos de mielina, Citocines sèriques; Pronòstic; Glicoproteïna d'oligodendròcits de mielina, Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling–matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non–optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions., This study has been funded by Instituto Carlos III through the projects PI20/00800 granted to A.C.-C. and Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP) (ARSEP-1276). A. Cobo-Calvo is supported by Joan Rodes contract JR19/00007 and Javier Villacieros-Álvarez by P-FIS grant FI21/00282.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology

  • Soler Luque, Zaida
  • Pons Tarín, Marc
  • Mayorga Ayala, Luis Fernando
  • Consegal, Marta
  • Manjon, Isaac
  • Serrano Gómez, Gerard
  • Yañez, Francisca
  • Herrera-deGuise, Claudia
  • BORRUEL, NATALIA
  • Rodriguez-Sinovas, Antonio
  • Vega Abellaneda, Sara
  • Chaysavanh, Manichanh
Inflammatory bowel disease; Microbiome; Multi-omics, Enfermedad inflamatoria intestinal; Microbioma; Multiómica, Malaltia inflamatòria intestinal; Microbioma; Multiòmica, Background The gut microbiome plays a key role in the development of inflammatory bowel disease (IBD), as imbalances in microbial composition are associated with immune dysfunction. However, the specific mechanisms by which certain microorganisms contribute to this process remain unclear. Methods Here, we employed a multi-omics approach on fecal samples to identify novel microbiome markers and elucidate mechanisms underlying IBD. Shotgun metagenomics was applied to 212 samples (850 in total with validation cohort), shotgun metatranscriptomics to 103 samples and metabolomics to 105 samples. Machine learning techniques were used to predict disease and the three omics data were integrated to propose a mechanistic role of the microbiota. Results Metagenomic analysis identified Crohn's disease (CD)-specific microbiome signatures, including a panel of 20 species that achieved a high diagnostic performance, with an area under the ROC curve (AUC) of 0.94 in an external validation set. Metatranscriptomic analysis revealed significant alterations in microbial fermentation pathways in CD, but not in ulcerative colitis (UC), highlighting disruptions that explain the depletion of butyrate—a key anti-inflammatory metabolite—observed in metabolomics analysis. Integrative multi-omics analyses further identified active virulence factor genes in CD, predominantly originating from the adherent-invasive Escherichia coli (AIEC). Notably, these findings unveiled novel mechanisms, including E. coli-mediated aspartate depletion and the utilization of propionate, which drives the expression of the ompA virulence gene, critical for bacterial adherence and invasion of the host’s macrophages. Interestingly, these microbiome alterations were absent in UC, underscoring distinct mechanisms of disease development between the two IBD subtypes. Conclusions In conclusion, our study not only identifies promising novel biomarkers with strong diagnostic potential, which could be valuable in challenging clinical scenarios, but also offers an integrated multi-omics perspective on the microbial mechanisms underlying inflammation and virulence in Crohn's disease., This work was supported by the Instituto de Salud Carlos III/FEDER (PI20/00130; FI21/00262). Marc Pons and Sara Vega-Abellaneda were supported by the AGAUR (2021 SGR 00459). Francisca Yáñez was supported by a fellowship from ANID, BECAS Chile, No. 72190278.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder

  • Carta, Sara
  • Dinoto, Alessandro
  • Capobianco, Marco
  • Valentino, Paola
  • Montarolo, Francesca
  • Sala, Arianna
  • Villacieros-Álvarez, Javier
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
Serum biomarker; Neuromyelitis optica spectrum disorder, Biomarcadores séricos; Trastorno del espectro de neuromielitis óptica, Biomarcadors sèrics; Trastorn de l'espectre de neuromielitis òptica, Background and Objectives Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) serum levels are useful to define disease activity in different neurologic conditions. These biomarkers are increased in patients with aquaporin-4 antibody–positive NMOSD (AQP4+NMOSD) during clinical attacks suggesting a concomitant axonal and glial damage. However, there are contradictory results in double seronegative NMOSD (DS-NMOSD). The aim of this study was to characterize the neuronal, axonal, and glial damage of DS-NMOSD in comparison with AQP4+NMOSD. Methods Patients with DS-NMOSD (i.e., for AQP4 and myelin oligodendrocyte glycoprotein antibodies—MOG-Abs) and age-matched AQP4+NMOSD diagnosed according to the latest diagnostic criteria and with available serum samples obtained within 3 months from onset/relapse were retrospectively enrolled from 14 international centers. Clinical and radiologic data were collected. Serum NfL, GFAP, tau, and UCH-L1 levels were determined using an ultrasensitive paramagnetic bead–based ELISA (SIMOA). Statistical analysis was performed using nonparametric tests and receiver-operating characteristic (ROC) curve analysis. Results We included 25 patients with AQP4+NMOSD and 26 with DS-NMOSD. The median age at disease onset (p = 0.611) and female sex predominance (p = 0.072) were similar in the 2 groups. The most common syndromes at sampling in both AQP4+NMOSD and DS-NMOSD were myelitis (56% vs 38.5%) and optic neuritis (34.6% vs 32%), with no statistical differences (p = 0.716). Median EDSS at sampling was 3.2 (interquartile range [IQR] 2–7.7) in the AQP4+NMOSD group and 4 (IQR [3–6]) in the DS-NMOSD group (p = 0.974). Serum GFAP, tau, and UCH-L1 levels were higher in patients with AQP4+NMOSD compared with those with DS-NMOSD (median 308.3 vs 103.4 pg/mL p = 0.001; median 1.2 vs 0.5 pg/mL, p = 0.001; and median 61.4 vs 35 pg/mL, p = 0.006, respectively). The ROC curve analysis showed that GFAP, tau, and UCH-L1, but not NfL, values were able to discriminate between AQP4+ and DS-NMOSD (area under the curve (AUC) tau: 0.782, p = 0.001, AUC GFAP: 0.762, p = 0.001, AUC UCH-L1: 0.723, p = 0.006). NfL levels were associated with EDSS at nadir only in patients with AQP4+NMOSD. Discussion Serum GFAP, tau, and UCH-L1 levels discriminate between AQP4+NMOSD and DS-NMOSD. The different biomarker profile of AQP4+NMOSD vs DS-NMOSD suggests heterogeneity of diseases within the latter category and provides useful data to improve our understanding of this disease., H. Zéphir has no disclosure related to this work. Unrelated to this work, H. Zéphir received consulting fees from Alexion, Horizon Therapeutics, Roche, Merck, Biogen Idec, Sanofi, and Novartis. Georgina Arrambide has received speaking honoraria and compensation for consulting services or participation in advisory boards from Merck, Roche, and Horizon Therapeutics; travel support for scientific meetings from Novartis, Roche, and ECTRIMS; is the editor for Europe of the Multiple Sclerosis Journal - Experimental, Translational and Clinical; and is a member of the International Women in Multiple Sclerosis (iWiMS) Network executive committee and of the European Biomarkers in MS (BioMS-eu) Consortium steering committee; J. Villacieros-Álvarez has received a grant from Instituto de Salud Carlos III, Spain, FI21/00282; A. Cobo-Calvo has received a grant from Instituto de Salud Carlos III, Spain, JR19/00007; E.P. Flanagan has served on advisory boards for Alexion, Genentech, Horizon Therapeutics, and UCB. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. S. Mariotto received speaker honoraria from Novartis, Biogen, and Sanofi. Go to Neurology.org/NN for full disclosures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Insights into Insulin Resistance and Calcification in the Myocardium in Type 2 Diabetes, A Coronary Artery Analysis

  • Martín-Saladich, Queralt|||0000-0003-4798-1558
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Aguadé-Bruix, Santiago|||0000-0001-8617-6274
  • Simó-Servat, Olga|||0000-0003-3483-652X
  • Aparicio-Gómez, Carolina|||0000-0002-0845-2365
  • Hernández, Cristina|||0000-0002-3109-1721
  • Ramírez Serra, Clara|||0000-0001-8971-1711
  • Pizzi, María Nazarena|||0000-0001-5065-8546
  • Roque, Albert|||0000-0001-9738-3850
  • González Ballester, Miguel Ángel|||0000-0002-9227-6826
  • Herance, José Raul|||0000-0001-7178-3290
Type 2 diabetes (T2D) is responsible for high incidence of cardiovascular (CV) complications leading to heart failure. Coronary artery region-specific metabolic and structural assessment could provide deeper insight into the extent of the disease and help prevent adverse cardiac events. Therefore, in this study, we aimed at investigating such myocardial dynamics for the first time in insulin-sensitive (mIS) and insulin-resistant (mIR) T2D patients. We targeted global and region-specific variations using insulin sensitivity (IS) and coronary artery calcifications (CACs) as CV risk factor in T2D patients. IS was computed using myocardial segmentation approaches at both baseline and after an hyperglycemic-insulinemic clamp (HEC) on [ 18 F]FDG-PET images using the standardized uptake value (SUV) (ΔSUV = SUV - SUV) and calcifications using CT Calcium Scoring. Results suggest that some communicating pathways between response to insulin and calcification are present in the myocardium, whilst differences between coronary arteries were only observed in the mIS cohort. Risk indicators were mostly observed for mIR and highly calcified subjects, which supports previously stated findings that exhibit a distinguished exposure depending on the impairment of response to insulin, while projecting added potential complications due to arterial obstruction. Moreover, a pattern relating calcification and T2D phenotypes was observed suggesting the avoidance of insulin treatment in mIS but its endorsement in mIR subjects. The right coronary artery displayed more ΔSUV, whilst plaque was more present in the circumflex. However, differences between phenotypes, and therefore CV risk, were associated to left descending artery (LAD) translating into higher CACs regarding IR, which could explain why insulin treatment was effective for LAD at the expense of higher likelihood of plaque accumulation. Personalized approaches to assess T2D may lead to more efficient treatments and risk-prevention strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining fMRI and DISC1 gene haplotypes to understand working memory-related brain activity in schizophrenia

  • Guardiola-Ripoll, Maria|||0000-0001-6949-5687
  • Sotero-Moreno, Alejandro
  • Almodóvar Payá, Carmen|||0000-0002-1952-1581
  • Hostalet, Noemí
  • Guerrero-Pedraza, Amalia|||0000-0001-7567-9407
  • Ramiro, Núria
  • Ortiz-Gil, Jordi|||0000-0001-7910-8062
  • Arias, Barbara|||0000-0001-9181-2132
  • Madre Rull, Mercè|||0000-0002-4660-3216
  • Soler-Vidal, Joan
  • Salvador, Raymond|||0000-0001-5557-1562
  • McKenna, Peter J.
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Fatjó-Vilas, Mar|||0000-0001-9963-6241
The DISC1 gene is one of the most relevant susceptibility genes for psychosis. However, the complex genetic landscape of this locus, which includes protective and risk variants in interaction, may have hindered consistent conclusions on how DISC1 contributes to schizophrenia (SZ) liability. Analysis from haplotype approaches and brain-based phenotypes can contribute to understanding DISC1 role in the neurobiology of this disorder. We assessed the brain correlates of DISC1 haplotypes associated with SZ through a functional neuroimaging genetics approach. First, we tested the association of two DISC1 haplotypes, the HEP1 (rs6675281-1000731-rs999710) and the HEP3 (rs151229-rs3738401), with the risk for SZ in a sample of 138 healthy subjects (HS) and 238 patients. This approach allowed the identification of three haplotypes associated with SZ (HEP1-CTG, HEP3-GA and HEP3-AA). Second, we explored whether these haplotypes exerted differential effects on n-back associated brain activity in a subsample of 70 HS compared to 70 patients (diagnosis × haplotype interaction effect). These analyses evidenced that HEP3-GA and HEP3-AA modulated working memory functional response conditional to the health/disease status in the cuneus, precuneus, middle cingulate cortex and the ventrolateral and dorsolateral prefrontal cortices. Our results are the first to show a diagnosis-based effect of DISC1 haplotypes on working memory-related brain activity, emphasising its role in SZ.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biofabrication of Self-Assembling Covalent Protein Nanoparticles through Histidine-Templated Cysteine Coupling

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Rueda, Ariana|||0000-0001-7588-9279
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez-Alba, Lucía|||0000-0001-7353-1097
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Serna, Naroa|||0000-0001-5682-8198
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Nanoscale protein materials show increasing applications in biotechnology and biomedicine, addressing catalysis, drug delivery, or tissue engineering. Although protein oligomerization is reachable through several engineering approaches, including the use of divalent cations for histidine-rich stretches, the effectiveness of cation-His binding is influenced by protein conformation, media composition, and chelating agents. Thus, looking for powerful, green, cross-linker-free, and transversal oligomerization platforms, we have built a histidine-templated cysteine-coupling concept. On this basis, we have engineered a Cys-containing, H6-derived His-Cys hybrid tag that enables the spontaneous and efficient self-assembling of tagged proteins into monodisperse nanoparticles through a highly ordered covalent binding process. Although the generated nanostructures are supported by disulfide bridge formation and exclusively reversed by reducing agents but not by chelating agents, the presence of cysteine residues does not disrupt the metal-binding abilities of histidine residues within the tag. This fact allows one to combine the one-step IMAC-based protein purification and, also, the Zn2+-induced formation of higher-order microparticulate materials as nanoparticle-releasing protein-only depots. The dual mode of cross-molecular interactivity shown by the hybrid tag and the structural robustness and stability of the resulting nanoparticles offer wide applicability of the green biofabrication concept proposed here for the further development of clinically usable protein materials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs)

  • Rueda, Ariana|||0000-0001-7588-9279
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Paez, David|||0000-0002-5596-6588
  • Aviñó, Ana|||0000-0003-3047-738X
  • Eritja, Ramon|||0000-0001-5383-9334
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The development of a new generation of non-antibody protein drug delivery systems requires site-directed conjugation strategies to produce homogeneous, reproducible and scalable nanomedicines. For that, the genetic addition of cysteine residues into solvent-exposed positions allows the thiol-mediated cysteine coupling of therapeutic drugs into protein-based nanocarriers. However, the high reactivity of unpaired cysteine residues usually reduces protein stability, consequently imposing the use of more methodologically demanding purification procedures. This is especially relevant for disulfide-containing nanocarriers, as previously observed in THIOMABs. Moreover, although many protein scaffolds and targeting ligands are also rich in disulfide bridges, the use of these methodologies over emerging non-antibody carrier proteins has been completely neglected. Here, we report the development of a simple and straightforward procedure for a one-step production and site-directed cysteine conjugation of disulfide-containing non-antibody thiolated carrier proteins (THIOCAPs). This method is validated in a fluorescent C-X-C chemokine receptor 4 (CXCR4)-targeted multivalent nano-carrier containing two intramolecular disulfide bridges and one reactive cysteine residue strategically placed into a solvent-exposed position (THIO-T22-GFP-H6) for drug conjugation and in a humanized alternative intended for clinical applications (T22-HSNBT-H6). Thus, we produce very stable, homogeneous and fully functional antitumoral nanoconjugates (THIO-T22-GFP-H6-MMAE and T22-HSNBT-H6-MMAE) that selectively eliminate target cancer cells via CXCR4-receptor. Altogether, the developed methodology appears as a powerful tool for the rational engineering of emerging non-antibody, cell-targeted protein nanocarriers that contain disulfide bridges together with a solvent-exposed reactive cysteine (THIOCAP). This should pave the way for the development of a new generation of stable, homogeneous and efficient nanomedicines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

  • Mensali, Nadia|||0000-0002-3130-4352
  • Köksal, Hakan
  • Joaquina, Sandy
  • Wernhoff, Patrick|||0000-0002-8111-9841
  • Casey, Nicholas P.
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Panisello, Carla|||0000-0002-8437-4418
  • Rodríguez, René|||0000-0002-0768-7306
  • Vimeux, Lene
  • Juzeniene, Asta
  • Myhre, Marit R.
  • Fåne, Anne
  • Castilla-Ramirez, Carolina
  • Maggadottir, Solrun Melkork
  • Duru, Adil Doganay|||0000-0002-5844-913X
  • Georgoudaki, Anna-Maria
  • Grad, Iwona
  • Maturana, Andrés Daniel
  • Gaudernack, Gustav
  • Kvalheim, Gunnar
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • De Álava, Enrique|||0000-0001-8400-046X
  • Donnadieu, Emma|||0000-0002-4985-7254
  • Bruland, Øyvind S.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Inderberg, Else Marit
  • Wälchli, Sébastien|||0000-0001-5869-1746
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase, Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model

  • Jung-KC, Kunwar|||0000-0002-6745-7318
  • Tristán Noguero, Alba|||0000-0002-0170-9762
  • Altankhuyag, Altanchimeg
  • Piñol Belenguer, David|||0000-0001-7490-5054
  • Prestegård, Karina S.|||0000-0003-3706-6751
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Colini Baldeschi, Arianna|||0000-0002-8638-3705
  • Sigatulina Bondarenko, Maria
  • García-Cazorla, Angels|||0000-0001-9853-688X
  • Consiglio, Antonella
  • Martinez, Aurora|||0000-0003-1643-6506
Proteostatic regulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is crucial for maintaining proper brain neurotransmitter homeostasis. Variants of the TH gene are associated with tyrosine hydroxylase deficiency (THD), a rare disorder with a wide phenotypic spectrum and variable response to treatment, which affects protein stability and may lead to accelerated degradation, loss of TH function and catecholamine deficiency. In this study, we investigated the effects of the TH cofactor tetrahydrobiopterin (BH) on the stability of TH in isolated protein and in DAn- differentiated from iPSCs from a human healthy subject, as well as from THD patients with the R233H variant in homozygosity (THDA) and R328W and T399M variants in heterozygosity (THDB). We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells. To translate this in vitro effect, we treated with BH a knock-in THD mouse model with Th variant corresponding to R233H in patients. Importantly, treatment with BH significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy). In conclusion, our study demonstrates the stabilizing effects of BH on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes. These findings highlight the therapeutic potential of BH as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

  • Lunemann, Jan
  • Valls Carbó, Adrián
  • Fernández, Victoria
  • Villacieros-Álvarez, Javier
  • Sepulveda, Maria
  • Dinoto, Alessandro
  • Vilaseca Jolonch, Andreu
  • Castillo Juárez, Mireia
  • Espejo, Carmen
  • Cobo-Calvo, Alvaro
  • Tintore, Mar
  • Comabella Lopez, Manuel
  • Arrambide, Georgina
  • Montalban, Xavier
  • Bollo, Luca
Complement activation; Clinical outcomes; Myelin oligodendrocyte glycoprotein, Perfiles de activación; Resultados clínicos; Glucoproteína de oligodendrocito de mielina, Activació del complement; Resultats clínics; Glicoproteïna d'oligodendròcits de mielina, Background and Objectives The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD. Methods Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples. A panel of CFs were measured by multiplex ELISA, and the levels were compared between the 3 conditions. Univariable and multivariable analyses were performed to evaluate the association between levels of CFs and relapse and disability outcomes in MOGAD patients. Results Ninety-four patients (MOGAD, n = 60; MS, n = 18; AQP4-NMOSD, n = 16) were included. Mean (SD) age at sampling was 39.4 (16.7), 40.7 (7.0), and 43.3 (21.0), respectively. Female were predominant, especially in AQP4-NMOSD (88%). Combination of the serum levels of C3a, C4a, and C3a/C3 ratio showed excellent potential to discriminate MOGAD from patients with MS (area under the curve [AUC] [95% CI] 0.95 [0.90–0.99]) and from AQP4-NMOSD (AUC 0.88 [0.76–1.00]). In patients with MOGAD, CSF levels of CFs of the classical/lectin pathway influenced relapse-related outcomes, and lower C4 levels were associated with higher number of relapses during follow-up (incidence rate ratio [95% CI] 0.88 [0.78–0.99]; p = 0.04 in multivariable analysis), and a high C4a/C4 ratio was associated with increased risk of second relapse during the first year (hazard ratio [95% CI] 3.68 [1.26–10.78]; p = 0.02 in multivariable analysis). Time to second relapse was shorter in patients with MOGAD with a high CSF C4a/C4 ratio (log-rank p = 0.01). CSF levels of the membrane attack complex SC5b9 influenced disability-related outcomes, and baseline CSF SC5b9 levels were higher in patients who reached the final Expanded Disability Status Scale (EDSS) ≥ 3.0 (p = 0.002), and elevated SC5b9 levels were associated with increased risk of reaching EDSS ≥ 3.0 (odds ratio [95% CI] 1.79 [1.16–3.67]; p = 0.04 in multivariable analyses). Discussion Our results suggest that serum and CSF levels of CFs have diagnostic and prognostic value respectively in patients with MOGAD. These findings support the use of complement inhibitors as a therapeutic approach in these patients., The study was funded thanks to a legacy from Mrs. Adela Arbó. J.V.-A. received grant from Instituto de Salud Carlos III, Spain; FI21/00282.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology

  • Soler Luque, Zaida
  • Pons Tarín, Marc
  • Mayorga Ayala, Luis Fernando
  • Consegal, Marta
  • Manjon, Isaac
  • Serrano Gómez, Gerard
  • Yañez, Francisca
  • Herrera-deGuise, Claudia
  • BORRUEL, NATALIA
  • Rodriguez-Sinovas, Antonio
  • Vega Abellaneda, Sara
  • Chaysavanh, Manichanh
Inflammatory bowel disease; Microbiome; Multi-omics, Enfermedad inflamatoria intestinal; Microbioma; Multiómica, Malaltia inflamatòria intestinal; Microbioma; Multiòmica, Background The gut microbiome plays a key role in the development of inflammatory bowel disease (IBD), as imbalances in microbial composition are associated with immune dysfunction. However, the specific mechanisms by which certain microorganisms contribute to this process remain unclear. Methods Here, we employed a multi-omics approach on fecal samples to identify novel microbiome markers and elucidate mechanisms underlying IBD. Shotgun metagenomics was applied to 212 samples (850 in total with validation cohort), shotgun metatranscriptomics to 103 samples and metabolomics to 105 samples. Machine learning techniques were used to predict disease and the three omics data were integrated to propose a mechanistic role of the microbiota. Results Metagenomic analysis identified Crohn's disease (CD)-specific microbiome signatures, including a panel of 20 species that achieved a high diagnostic performance, with an area under the ROC curve (AUC) of 0.94 in an external validation set. Metatranscriptomic analysis revealed significant alterations in microbial fermentation pathways in CD, but not in ulcerative colitis (UC), highlighting disruptions that explain the depletion of butyrate—a key anti-inflammatory metabolite—observed in metabolomics analysis. Integrative multi-omics analyses further identified active virulence factor genes in CD, predominantly originating from the adherent-invasive Escherichia coli (AIEC). Notably, these findings unveiled novel mechanisms, including E. coli-mediated aspartate depletion and the utilization of propionate, which drives the expression of the ompA virulence gene, critical for bacterial adherence and invasion of the host’s macrophages. Interestingly, these microbiome alterations were absent in UC, underscoring distinct mechanisms of disease development between the two IBD subtypes. Conclusions In conclusion, our study not only identifies promising novel biomarkers with strong diagnostic potential, which could be valuable in challenging clinical scenarios, but also offers an integrated multi-omics perspective on the microbial mechanisms underlying inflammation and virulence in Crohn's disease., This work was supported by the Instituto de Salud Carlos III/FEDER (PI20/00130; FI21/00262). Marc Pons and Sara Vega-Abellaneda were supported by the AGAUR (2021 SGR 00459). Francisca Yáñez was supported by a fellowship from ANID, BECAS Chile, No. 72190278.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease

  • Mulero, Patricia
  • Rubio-Flores, Laura
  • Villacieros-Álvarez, Javier
  • Espejo, Carmen
  • Dinoto, Alessandro
  • Rovira, Alex
  • Auger, Cristina
  • Tintore, Mar
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
  • Montalban, Xavier
Serum Cytokines; Prognosis; Myelin oligodendrocyte glycoprotein, Citocinas séricas; Pronóstico; Glicoproteína de oligodendrocitos de mielina, Citocines sèriques; Pronòstic; Glicoproteïna d'oligodendròcits de mielina, Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling–matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non–optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions., This study has been funded by Instituto Carlos III through the projects PI20/00800 granted to A.C.-C. and Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP) (ARSEP-1276). A. Cobo-Calvo is supported by Joan Rodes contract JR19/00007 and Javier Villacieros-Álvarez by P-FIS grant FI21/00282.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder

  • Carta, Sara
  • Dinoto, Alessandro
  • Capobianco, Marco
  • Valentino, Paola
  • Montarolo, Francesca
  • Sala, Arianna
  • Villacieros-Álvarez, Javier
  • Cobo-Calvo, Alvaro
  • Arrambide, Georgina
Serum biomarker; Neuromyelitis optica spectrum disorder, Biomarcadores séricos; Trastorno del espectro de neuromielitis óptica, Biomarcadors sèrics; Trastorn de l'espectre de neuromielitis òptica, Background and Objectives Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) serum levels are useful to define disease activity in different neurologic conditions. These biomarkers are increased in patients with aquaporin-4 antibody–positive NMOSD (AQP4+NMOSD) during clinical attacks suggesting a concomitant axonal and glial damage. However, there are contradictory results in double seronegative NMOSD (DS-NMOSD). The aim of this study was to characterize the neuronal, axonal, and glial damage of DS-NMOSD in comparison with AQP4+NMOSD. Methods Patients with DS-NMOSD (i.e., for AQP4 and myelin oligodendrocyte glycoprotein antibodies—MOG-Abs) and age-matched AQP4+NMOSD diagnosed according to the latest diagnostic criteria and with available serum samples obtained within 3 months from onset/relapse were retrospectively enrolled from 14 international centers. Clinical and radiologic data were collected. Serum NfL, GFAP, tau, and UCH-L1 levels were determined using an ultrasensitive paramagnetic bead–based ELISA (SIMOA). Statistical analysis was performed using nonparametric tests and receiver-operating characteristic (ROC) curve analysis. Results We included 25 patients with AQP4+NMOSD and 26 with DS-NMOSD. The median age at disease onset (p = 0.611) and female sex predominance (p = 0.072) were similar in the 2 groups. The most common syndromes at sampling in both AQP4+NMOSD and DS-NMOSD were myelitis (56% vs 38.5%) and optic neuritis (34.6% vs 32%), with no statistical differences (p = 0.716). Median EDSS at sampling was 3.2 (interquartile range [IQR] 2–7.7) in the AQP4+NMOSD group and 4 (IQR [3–6]) in the DS-NMOSD group (p = 0.974). Serum GFAP, tau, and UCH-L1 levels were higher in patients with AQP4+NMOSD compared with those with DS-NMOSD (median 308.3 vs 103.4 pg/mL p = 0.001; median 1.2 vs 0.5 pg/mL, p = 0.001; and median 61.4 vs 35 pg/mL, p = 0.006, respectively). The ROC curve analysis showed that GFAP, tau, and UCH-L1, but not NfL, values were able to discriminate between AQP4+ and DS-NMOSD (area under the curve (AUC) tau: 0.782, p = 0.001, AUC GFAP: 0.762, p = 0.001, AUC UCH-L1: 0.723, p = 0.006). NfL levels were associated with EDSS at nadir only in patients with AQP4+NMOSD. Discussion Serum GFAP, tau, and UCH-L1 levels discriminate between AQP4+NMOSD and DS-NMOSD. The different biomarker profile of AQP4+NMOSD vs DS-NMOSD suggests heterogeneity of diseases within the latter category and provides useful data to improve our understanding of this disease., H. Zéphir has no disclosure related to this work. Unrelated to this work, H. Zéphir received consulting fees from Alexion, Horizon Therapeutics, Roche, Merck, Biogen Idec, Sanofi, and Novartis. Georgina Arrambide has received speaking honoraria and compensation for consulting services or participation in advisory boards from Merck, Roche, and Horizon Therapeutics; travel support for scientific meetings from Novartis, Roche, and ECTRIMS; is the editor for Europe of the Multiple Sclerosis Journal - Experimental, Translational and Clinical; and is a member of the International Women in Multiple Sclerosis (iWiMS) Network executive committee and of the European Biomarkers in MS (BioMS-eu) Consortium steering committee; J. Villacieros-Álvarez has received a grant from Instituto de Salud Carlos III, Spain, FI21/00282; A. Cobo-Calvo has received a grant from Instituto de Salud Carlos III, Spain, JR19/00007; E.P. Flanagan has served on advisory boards for Alexion, Genentech, Horizon Therapeutics, and UCB. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. S. Mariotto received speaker honoraria from Novartis, Biogen, and Sanofi. Go to Neurology.org/NN for full disclosures.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A contributory citizen science project reveals the impact of dietary keys to microbiome health in Spain

  • Pons Tarín, Marc
  • Cognard, Chloe
  • Noguera Segura, Arnau
  • Roca-Bosch, Melina
  • Soler, Zaida
  • Serrano Gómez, Gerard
  • Vega Abellaneda, Sara
  • xie, zixuan
  • Manjon, Isaac
  • Varela Castro, Encarna
  • Yañez, Francisca
  • Chaysavanh, Manichanh
Contributory citizen science; Dietary keys; Microbiome, Ciencia ciudadana contributiva; Claves dietéticas; Microbioma, Ciència ciutadana contributiva; Claus dietètiques; Microbioma, Low consumption of whole grains, fruits, and vegetables has been identified as dietary risks for non-communicable diseases such as inflammatory bowel diseases (IBDs). We explore how individual and lifestyle factors influence these risks by shaping gut microbiome composition. 1001 healthy participants from all Spanish regions provided personal and dietary data at baseline, six, and twelve months, yielding 2475 responses. Gut microbiome data were analyzed for 500 healthy participants and 321 IBD patients. Our findings reveal that adherence to national dietary guidelines—characterized by diets rich in nuts, seeds, fruits, and vegetables—was associated with greater microbial diversity and reduced IBD-related dysbiosis. Finally, we observed variations in dietary patterns and microbiome diversity and composition across age groups, genders, regions, seasons, and transit time. This study is among the first to uncover dietary intake associated with IBD-related dysbiosis and to propose an interactive website for participants (https://manichanh.vhir.org/POP/en)., This work was financially supported by the Instituto de Salud Carlos III and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future” (PI20/00130; FI21/00262) and by the AGAUR (2021 SGR 00459). Francisca Yáñez was supported by a fellowship from ANID, BECAS Chile, No. 72190278. None of the funders were private companies.